Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
The investigators will prospectively determine whether the relapse-free and overall survival
in patients who have cleared their leukemia-associated mutations treated with standard
consolidation chemotherapy is superior to what is expected based on historical controls. The
investigators will also prospectively determine the relapse-free and overall survival of
patients who have not cleared their mutations. Because the relapse rate of patients with
persistent mutations is expected to be high, treatment with either standard of care
consolidation therapy alone or alloSCT will be permitted, at the discretion of the treating
physician.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
American Society of Hematology The Leukemia and Lymphoma Society